source
- House lawmakers hear mixed views on credentialing for psychedelic providersAs psychedelic medicines move closer to market, two members of the U.S. House are outlining how the drugs might be rolled out and what accompanying legislation could look like. The focus of their…
- Merck reports positive mid-stage results for Prometheus' tulisokibart in painful skin diseaseMerck presented new data from a mid-stage trial of tulisokibart, a drug acquired through its $10.8 billion purchase of Prometheus Biosciences. The trial evaluated multiple dose levels in patients…